These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8241367)

  • 1. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies.
    Hsuan FC
    Biometrics; 1993 Sep; 49(3):703-13. PubMed ID: 8241367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S37-43. PubMed ID: 1601530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Welch-type test for homogeneity of contrasts under heteroscedasticity with application to meta-analysis.
    Kulinskaya E; Dollinger MB; Knight E; Gao H
    Stat Med; 2004 Dec; 23(23):3655-70. PubMed ID: 15534893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing individual bioequivalence with high-order cross-over designs: a unified procedure.
    Hsuan FC; Reeve R
    Stat Med; 2003 Sep; 22(18):2847-60. PubMed ID: 12953284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust alternatives to the F-Test in mixed linear models based on MM-estimates.
    Copt S; Heritier S
    Biometrics; 2007 Dec; 63(4):1045-52. PubMed ID: 17484776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing spatially distributed binary data using independent-block estimating equations.
    Oman SD; Landsman V; Carmel Y; Kadmon R
    Biometrics; 2007 Sep; 63(3):892-900. PubMed ID: 17489971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linear mixed models with heterogeneous within-cluster variances.
    Lin X; Raz J; Harlow SD
    Biometrics; 1997 Sep; 53(3):910-23. PubMed ID: 9290222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small sample inference for fixed effects from restricted maximum likelihood.
    Kenward MG; Roger JH
    Biometrics; 1997 Sep; 53(3):983-97. PubMed ID: 9333350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence.
    Endrenyi L; Hao Y
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):450-7. PubMed ID: 9726700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multivariate test for population bioequivalence.
    Chervoneva I; Hyslop T; Hauck WW
    Stat Med; 2007 Mar; 26(6):1208-23. PubMed ID: 16810712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A note on permutation tests for variance components in multilevel generalized linear mixed models.
    Fitzmaurice GM; Lipsitz SR; Ibrahim JG
    Biometrics; 2007 Sep; 63(3):942-6. PubMed ID: 17403100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of recent methods for the analysis of small-sample cross-over studies.
    Chen X; Wei L
    Stat Med; 2003 Sep; 22(18):2821-33. PubMed ID: 12953282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.